Experienced in Mesothelioma

Olivier Bylicki

Toulon, FR 
Experienced in Mesothelioma
Toulon, FR 
OverviewLocationsClinical Research

Overview

Olivier Bylicki practices in Toulon, France. Mr. Bylicki is rated as an Experienced expert by MediFind in the treatment of Mesothelioma. His top areas of expertise are Solitary Fibrous Tumor, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Endoscopy.

His clinical research consists of co-authoring 73 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Mesothelioma.

Gender
Male

Locations

Toulon, France
Other Locations
Paris, France
Lyon, France
4 Rue Larrey, Angers, 49100, France
101 Avenue Henri Barbusse, Clamart, 92140, France
University Paris Est Créteil, EA 7376- IMRB, UPEC, Creteil, France
Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2025
Intervention Type: Other
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
View 2 Less Clinical Trials

73 Total Publications

Response to the Letter of Mehmet Mutlu Çatlı, Arif Hakan Önder.
Response to the Letter of Mehmet Mutlu Çatlı, Arif Hakan Önder.
Journal: Clinical lung cancer
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bylicki's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile